Pegcetacoplan Acetate combines a complement-targeting peptide core with a PEGylated architecture that enhances solubility and hydrodynamic size. The conjugated polyethylene glycol segment reduces aggregation and modulates pharmacokinetic modeling in vitro. Researchers study its binding equilibria to complement proteins and structural organization in solution. Applications include complement-pathway mechanism research, ligand-protein interaction mapping, and bioconjugate optimization.
CAT No: R2537
Pegcetacoplan acetate is a synthetic cyclic peptide conjugated to polyethylene glycol (PEG), designed to function as a targeted complement C3 inhibitor. As a chemically modified peptide, it exhibits high specificity and affinity for the central component of the complement cascade, C3, thereby modulating complement system activity. Its unique structure, combining a macrocyclic peptide backbone with PEGylation, enhances its stability and pharmacokinetic properties in biochemical systems. Pegcetacoplan acetate is of significant interest to researchers investigating complement biology, immune regulation, and the development of advanced tools for dissecting complement-mediated pathways in vitro and in preclinical models.
Complement inhibition research: Pegcetacoplan acetate is widely utilized in studies aiming to elucidate the molecular mechanisms of complement activation and regulation. By selectively binding to C3 and preventing its cleavage, it enables precise modulation of the complement cascade in cellular and biochemical assays. Researchers employ it to dissect the downstream effects of C3 inhibition, investigate alternative pathway dynamics, and map the roles of complement proteins in innate immunity. Its use allows for controlled perturbation of complement activity, providing critical insights into immune complex processing, opsonization, and inflammatory signaling.
Immunology and inflammation studies: The compound serves as a valuable tool for probing the contribution of complement-mediated processes to inflammation and immune cell activation. In vitro and ex vivo models incorporate pegcetacoplan acetate to evaluate how C3 blockade affects cytokine release, leukocyte recruitment, and tissue damage in response to various stimuli. Its application supports the investigation of the interplay between complement factors and other immune mediators, facilitating the identification of potential regulatory nodes within inflammatory pathways.
Peptide-drug conjugate research: As a PEGylated cyclic peptide, pegcetacoplan acetate is of interest in the field of peptide-drug conjugate design and optimization. Its structure offers a model for studying the impact of PEGylation on peptide stability, solubility, and resistance to proteolytic degradation. Researchers use it to benchmark and develop next-generation peptide therapeutics with improved pharmacological properties, leveraging its chemical features to inform conjugation strategies and delivery system design.
Biochemical assay development: The specific inhibitory action of pegcetacoplan acetate on C3 makes it a preferred reagent in the development of biochemical and cell-based assays targeting the complement system. It is incorporated into experimental protocols to validate assay sensitivity, establish controls for complement inhibition, and assess the efficacy of novel complement-modulating compounds. Its predictable activity profile enhances the reliability and reproducibility of complement-targeted analytical methods.
Proteomics and biomarker discovery: In proteomics workflows, pegcetacoplan acetate is employed to modulate complement activity in biological samples, thereby enabling the identification and quantification of complement-derived peptides and related biomarkers. By selectively suppressing C3 activation, it helps distinguish between complement-dependent and independent protein changes, supporting the discovery of novel biomarkers and the characterization of disease-relevant proteolytic events. Its application in mass spectrometry-based studies aids in unraveling complex protein networks influenced by complement dynamics.
2. High fat diet and GLP-1 drugs induce pancreatic injury in mice
3. Immune-awakening Saccharomyces-inspired nanocarrier for oral target delivery to lymph and tumors
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More